Overview
Quantum-Si Q3 revenue was $552,000
Net loss widened to $35.7 mln from $25.3, reflecting increased operating expenses
Company achieved successful sequencing on prototype Proteus unit, development on track
Outlook
Quantum-Si plans to launch version 3 Library Prep Kit by year-end 2025
Company expects to deliver Proteus platform in second half of 2026
Quantum-Si using instrument acquisition options to counter NIH funding uncertainty
Result Drivers
VERSION 4 KIT LAUNCH - Launch of version 4 Sequencing Kit contributed to quarterly results
OPERATING EXPENSES - Rose to $40 mln from $28.5 mln a year ago, pressuring earnings
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $552,000 | ||
Q3 EPS | -$0.17 | ||
Q3 Net Income | -$35.70 mln | ||
Q3 Operating Expenses | $39.97 mln | ||
Q3 Operating Income | -$39.77 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Quantum-Si Inc is $3.00, about 38.7% above its November 4 closing price of $1.84
Press Release: ID:nBwbC1ctVa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)